Pemigatinib 4.5 MG
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer
Trial Timeline
Jun 14, 2022 → Aug 31, 2025
NCT ID
NCT05216120About Pemigatinib 4.5 MG
Pemigatinib 4.5 MG is a phase 2 stage product being developed by Incyte for Pancreas Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05216120. Target conditions include Pancreas Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05216120 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Pancreas Cancer